Types of Multiple Myeloma

Key Takeaways

• Multiple myeloma is classified primarily by the type of abnormal protein (immunoglobulin) that cancerous plasma cells produce.
• The most common subtype is IgG myeloma, followed by IgA myeloma, each with distinct clinical behaviors.
• Light chain multiple myeloma is a significant variant in which plasma cells produce only partial antibody chains, often causing kidney complications.
• Smoldering myeloma is an asymptomatic precursor state that requires monitoring but not immediate treatment in most cases.
• Accurate classification directly shapes treatment planning, risk stratification, and long-term management strategies.

Main Types of Multiple Myeloma by Protein Class

Multiple myeloma subtypes and classifications are largely defined by the type of immunoglobulin (antibody) that the malignant plasma cells overproduce. Normal plasma cells produce complete antibodies made up of heavy chains and light chains. In myeloma, this production becomes dysregulated, generating a specific abnormal protein — known as an M protein or paraprotein — that serves as a diagnostic and classification marker.

The most prevalent subtype is IgG myeloma, which accounts for approximately 52% of all myeloma cases, according to data published by the American Cancer Society. IgG myeloma tends to follow a relatively predictable clinical course and generally responds well to standard therapy. The second most common form is IgA myeloma, representing around 21% of cases. IgA myeloma is associated with a somewhat higher risk of hyperviscosity syndrome — a condition in which thickened blood impairs circulation — and may carry a slightly less favorable prognosis compared to IgG myeloma.

Less common heavy-chain subtypes include IgD, IgE, and IgM myeloma. IgD myeloma, though rare, is notable for its aggressive behavior and frequent association with Bence Jones proteinuria, a marker of light chain excretion in urine. IgE myeloma is exceptionally uncommon and often more difficult to diagnose due to its rarity. IgM myeloma overlaps clinically with Waldenström macroglobulinemia and requires careful differentiation. Each subtype carries unique biological characteristics that influence both the clinical presentation and the choice of treatment regimen.

Light Chain Multiple Myeloma and Other Variant Subtypes

Light chain multiple myeloma vs other types represents one of the most clinically significant distinctions in myeloma classification. In this subtype, malignant plasma cells produce only free light chains — either kappa (κ) or lambda (λ) — rather than complete immunoglobulin molecules. This accounts for approximately 16% of myeloma cases. Because free light chains are small molecules, they pass readily through kidney filters and can accumulate in renal tubules, making kidney damage a leading complication in this group.

Patients with light chain myeloma often have undetectable M protein on standard serum protein electrophoresis, which can complicate initial diagnosis. Instead, diagnosis relies on serum free light chain assays and urine tests for Bence Jones protein. The kappa-to-lambda free light chain ratio is a key monitoring tool throughout treatment, as it reflects disease burden more accurately than traditional markers in this subtype. Patients may also experience amyloidosis — a condition in which misfolded light chain proteins deposit in organs — which can affect the heart, kidneys, and nervous system.

Another variant worth noting is non-secretory myeloma, in which plasma cells do not produce or release detectable levels of M protein into the blood or urine. This subtype affects approximately 3% of patients and requires bone marrow biopsy and imaging — including PET-CT or MRI — for accurate assessment of disease burden. Despite the absence of a detectable paraprotein, non-secretory myeloma can be equally aggressive and carries treatment considerations comparable to secretory subtypes.

Smoldering vs. Active Multiple Myeloma: Key Differences

Smoldering multiple myeloma vs active myeloma is a distinction that significantly affects clinical management. Smoldering multiple myeloma (SMM) is an intermediate, asymptomatic stage characterized by elevated M protein levels and increased bone marrow plasma cells — typically 10–60% — but without the end-organ damage that defines active disease. Active myeloma, by contrast, is defined by the presence of myeloma-related organ or tissue impairment, often summarized using the CRAB criteria: elevated Calcium, Renal insufficiency, Anemia, and Bone lesions.

The risk of SMM progressing to active myeloma varies considerably. Studies published in the New England Journal of Medicine have shown that high-risk SMM patients carry up to a 50% risk of progression within two years, while low-risk patients may remain stable for a decade or more. Risk stratification tools, including the Mayo Clinic 20/2/20 model, help clinicians identify which SMM patients may benefit from early therapeutic intervention versus continued observation alone.

Beyond SMM, it is important to distinguish myeloma from its earlier precursor, monoclonal gammopathy of undetermined significance (MGUS). MGUS involves lower levels of M protein (under 3 g/dL) and fewer than 10% plasma cells in the bone marrow, with no end-organ damage. MGUS progresses to myeloma or a related disorder at a rate of approximately 1% per year. Regular monitoring is essential for both MGUS and SMM to detect any transition to active disease promptly.

How Multiple Myeloma Classifications Guide Treatment

Multiple myeloma classifications guide treatment by determining which therapeutic agents, monitoring strategies, and risk-adapted approaches are most appropriate for each patient. The immunoglobulin subtype, cytogenetic profile, and disease stage each contribute to individualized treatment planning. For example, patients with high-risk cytogenetic abnormalities — such as deletion 17p or translocation t(4;14) — may require more intensive regimens or novel agent combinations compared to standard-risk individuals.

The distinction between IgG vs IgA multiple myeloma differences extends beyond biology into treatment monitoring. IgG myeloma can be tracked reliably using serum M protein quantification, while IgA levels may require immunofixation electrophoresis for accurate measurement due to comigration issues on standard tests. Similarly, light chain-only disease demands serum free light chain monitoring rather than traditional M protein tests, making subtype classification central to choosing appropriate response criteria during therapy.

Staging systems also intersect with classification. The Revised International Staging System (R-ISS) incorporates serum albumin, beta-2 microglobulin, lactate dehydrogenase, and cytogenetics to assign patients to Stage I, II, or III — each correlating with distinct median survival outcomes. Smoldering patients are not staged using R-ISS in clinical practice but are risk-stratified separately. Taken together, these classification frameworks allow oncologists to tailor induction therapy, consolidation, maintenance, and transplant eligibility decisions with precision aligned to each patient’s disease biology.

Frequently Asked Questions

Is multiple myeloma always the same disease regardless of subtype?

No. Different types of multiple myeloma behave distinctly and require individualized approaches. Subtype classification based on immunoglobulin class, light chain status, and cytogenetics directly influences prognosis and treatment selection. For instance, IgD and light chain subtypes often carry higher risks of certain complications compared to IgG myeloma, underscoring why accurate subtype identification is a foundational step in every patient’s care plan.

Can smoldering myeloma be treated, or only monitored?

Traditionally, smoldering myeloma was managed through active surveillance without treatment. However, clinical trials — including the QUIREDEX study — have demonstrated that early treatment of high-risk SMM may delay progression to active disease and improve outcomes. Treatment decisions depend on individual risk stratification. Patients classified as high-risk SMM should discuss the potential benefits of early intervention with their hematologist, as recommendations in this area continue to evolve with emerging evidence.

Are there types of multiple myeloma that are harder to diagnose?

Yes. Non-secretory myeloma and IgD myeloma are among the more diagnostically challenging subtypes. Non-secretory disease produces no detectable M protein, requiring imaging and bone marrow biopsy for diagnosis. IgD myeloma is rare and may be overlooked if standard immunofixation panels do not include IgD-specific testing. Light chain myeloma can also be missed without serum free light chain assays, highlighting the importance of comprehensive laboratory evaluation in all suspected myeloma cases.